Glaxosmithkline Pharmaceuticals Q2 FY27 earnings call: Revenue for Q2 FY27 grew 21% year-on-year to INR 1,180 crores, with underlying growth at 12%...
Results · Finvezto · 4 Nov 2026 · Glaxosmithkline Pharmaceuticals (GLAXO)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 1,180 | - | - |
| Operating profit | 400 | - | - |
| Operating margin | 33.9% | - | - |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Glaxosmithkline Pharmaceuticals Q2 FY27 earnings call: Revenue for Q2 FY27 grew 21% year-on-year to INR 1,180 crores, with underlying growth at 12% to 13% after adjusting for a low base and CMO fire... Source
- Revenue for Q2 FY27 grew 21% year-on-year to INR 1,180 crores, with underlying growth at 12% to 13% after adjusting for a low base and CMO fire impact. Earnings call
- EBITDA grew 20% to INR 400 crores with margins maintained at 34%, while profit after tax rose 33% aided by a one-off income tax refund interest of INR 42 crores. Earnings call
- The innovation portfolio doubled its revenue share to 7% from 3% last year, contributing one-quarter of total revenue growth over the past 12 to 18 months. Earnings call
What to watch
- Management on revenue ambition: So that remains undiluted, that ambition to grow 2x remains undiluted.
- Management on established products contribution: Our internal modelling suggests about three fifths of that growth, we will be able to -- we should be able to deliver from our current established products organically.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.